Prostate Cancer, Ovarian Cancer

Inclusion Criteria

- Males or females aged >/= 18 years
 - Epithelial ovarian, peritoneal cavity or Fallopian
tube cancer (except mucinous or clear cell 
tumors) or Adenocarcinoma of the prostate
 - At least 1 unidimensional  measurable lesion 
(suitable for RECIST evaluation) or for patients 
without measurable disease, CA 125 levels >/= 2  times the upper limit of normal (ULN) within 3
months and confirmed within 2 weeks prior to
first infusion (ovarian cancer) or PSA value >/= 5 ng/mL (HRPC). 
 - Progression of disease (HRPC) despite adequate androgen-inhibiting hormone therapy.  
 - Progression of disease (Ovarian Cancer) or 
symptomatic relapse after previous therapy
(elevated CA125 levels alone are insufficient for inclusion)  WHO performance status 0 to 1 
 - No clinical residual neuropathy (CTCAE Grade
0 at baseline)
 - Adequate recovery from previous surgery, 
radiation, and chemotherapy (excluding alopecia)
 - Adequate function of major organs and systems.
 - Survival expectation =3 months
 - Histologically or cytologically proven:
a) Epithelial ovarian, peritoneal cavity or Fallopian tube cancer (except mucionous cell tumors or clear cell tumors that have a clear cell component of >33%)

Exclusion Criteria

- Symptomatic brain metastases requiring whole-
brain irradiation 
 - Any concomitant malignancy: the following exceptions are allowed: Non-melanoma skin
cancer, Carcinoma in situ of the cervix, Malignancy with definitive treatment >/= 5 years ago without relapse.
 - Diabetes mellitus (even if controlled only by
special diet)
 - History of chronic hepatitis B or C, or known
 HIV infection 
 - Seizure disorder requiring medication (such as
steroids or anti-epileptics)
 - Inability to swallow oral medications
 - Prior treatment with epothilones
 - Concomitant use of neurotoxic drugs
 - Concomitant use of compounds that have
potentially positive effects towards symptoms
of neuropathy